Please ensure Javascript is enabled for purposes of website accessibility

Why Halozyme Therapeutics Inc. Sank 16.5% in May

By Brian Feroldi - Jun 6, 2017 at 9:14AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

News that a secondary stock offering would be taking place at a discounted price caused shares of the developmental stage biotech to swoon.

What happened

Halozyme Therapeutics (HALO 0.02%), a biotech focused on creating products that help other drugs work better, fell 16.5% in May according to data from S&P Global Market Intelligence

So what

Halozyme released its first quarter earnings results in May, but the report didn't appear to have anything to do with the decline. While revenue of $29.6 million and a net loss of $0.26 per share did come in a bit shy of expectations, the stock didn't move much in the days following the Q1 release.

Instead, investors can blame the drop on the pricing details related to its recently executed secondary stock offering. Halozyme said that it sold 10 million shares of common stock at $12.50 each, and also provided the underwriters of the deal with the option to purchase another 1.5 million shares. In total, up to $143.75 million could be added to the company's bank balance from this deal before subtracting fees. However, that $12.50 price tag was quite a bit below the $14.16 closing price that shares were fetching on the open market on the day prior to the capital raise announcement. The big gap between those two figures suggests that Halozyme had to offer a big discount on its shares in order to entice enough investors to participate.

Given the soft investor demand and dilution, it isn't surprising to see that shares took a step back during the month.

money falling out of businessman pocket

Image Source: Getty Images.

Now what

Halozyme expects to burn through at least $75 million in cash this year as it continues to develop its PEGPH20 product candidate. Given that it ended March with $179 million in cash, it's understandable that the company wanted to raise some capital. 

Halozyme's most important clinical trial is HALO-301, which is studying PEGPH20 in combination with Celgene's Abraxane as a treatment for pancreatic cancer. Thus far, it looks like the product candidate is on track to make it to market, but only time will tell if regulators think it is deserving of the green light. At least bulls can now sleep soundly knowing that the company has enough capital to keep its doors open for a few more years. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Halozyme Therapeutics, Inc. Stock Quote
Halozyme Therapeutics, Inc.
$44.33 (0.02%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/23/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.